Clinical Trial Update: Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis [Phase 2]

View source ↗

Summary

Phase 2 study of ABBV-668 oral capsules in adults with moderate-to-severe Ulcerative Colitis has completed with results posted, detailing adverse events and cha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• ABBV-668

Snippet

Sponsor: AbbVie | Conditions: Ulcerative Colitis | Phase 2 | Status: COMPLETED | Results posted: 2025-12-23